Table 2

Number of AEs per treatment

Study	Treatments (n)	AEs (n)		AE incidence per 100 treatments		Bleeding, pain and flare at needling site as % of all AE
Study	Treatments (n)	Total	Excluding bleeding, pain, and flare	Total	Excluding bleeding, pain, and flare	Bleeding, pain and flare at needling site as % of all AE
Park et al 200945	1095	193	64	17.63	5.84	66.84%
Ernst et al 200334	3535	632	403	17.88	11.40	36.23%
Melchart et al 199842	1200	120	66	10.00	5.50	45.00%
Yamashita et al 199951	65 482	94	67	0.14	0.10	28.72%
Yamashita et al 200050	1441	996	114	69.12	7.91	88.55%
MacPherson et al 200140	34 407	4544	3406	13.21	9.90	25.04%
Odsberg et al 200143	9277	2108	390	22.72	4.20	81.50%
White et al 200148	31 822	2176	820	6.84	2.58	62.32%
MacPherson and Thomas 200539	9408	5071	3473	53.90	36.92	31.51%
Leung et al 200936	2000	8	0	0.40	0.00	100.00%
Park et al 201044	3071	99	26	3.22	0.85	73.74%
da Silva et al 201432	13 884	1107	117	7.97	0.84	89.43%
Furuse et al 201735	14 039	854	232	6.08	1.65	72.83%
Overall	190 661	18 002	9178	9.44	4.81	49.02%

AE, adverse event.